切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2024, Vol. 18 ›› Issue (02) : 91 -99. doi: 10.3877/cma.j.issn.1674-1358.2024.02.005

论著

232例手足口病患儿流行特征及预后风险模型的构建与验证
吕巧荣1,†(), 张燕1, 付敏1   
  1. 1. 617067　攀枝花市，四川省攀枝花市中心医院公共卫生科
  • 收稿日期:2023-08-27 出版日期:2024-04-15
  • 通信作者: 吕巧荣
  • 基金资助:
    四川省科委社会类科技发展基金项目(No. SC528-0215B)

Construction and validation of epidemic characteristics and prognostic risk model of hand, foot and mouth disease

Qiaorong Lv1,†(), Yan Zhang1, Min Fu1   

  1. 1. Department of Public Health, Panzhihua Central Hospital, Panzhihua 617067, China
  • Received:2023-08-27 Published:2024-04-15
  • Corresponding author: Qiaorong Lv
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

吕巧荣, 张燕, 付敏. 232例手足口病患儿流行特征及预后风险模型的构建与验证[J]. 中华实验和临床感染病杂志(电子版), 2024, 18(02): 91-99.

Qiaorong Lv, Yan Zhang, Min Fu. Construction and validation of epidemic characteristics and prognostic risk model of hand, foot and mouth disease[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2024, 18(02): 91-99.

目的

探讨手足口病（HFMD）流行特征并分析影响其预后的危险因素，行风险模型的构建与验证。

方法

回顾性收集2017年1月至2023年10月四川省攀枝花市中心医院收治的232例HFMD患儿的临床资料，根据预后将入组患儿分为预后良好组178例（男106例，女72例）和预后不良组54例（男30例，女24例）；分析HFMD流行特征，比较两组患儿的临床资料，多因素Logistic回归分析影响HFMD预后的独立因素，并建立风险预测模型进行验证。

结果

入组患儿中< 1岁HFMD发病率显著高于1岁及以上患儿（P < 0.001），女性患儿发病率显著低于男性患儿（χ2 = 2.372、P=0.039），夏季发病率显著高于其他3个季节（χ2 = 9.231、P < 0.001），散居发病率高于托幼和其他居住类型儿童（P < 0.001）。多因素Logistic回归分析显示，年龄≤ 2岁（OR = 3.668、95%CI：1.110～5.332、P = 0.011）、白细胞介素-6（IL-6）> 25 ng/L（OR = 4.968、95%CI：2.382～6.470、P = 0.001）、肿瘤坏死因子α（TNF-α）> 175 ng/L（OR = 5.042、95%CI：3.265～7.044、P < 0.001）、血清淀粉样蛋白A（SAA）> 10 mg/L（OR = 3.970、95%CI：2.053～6.339、P = 0.013）、空腹血糖（FBG）≥6.10 mmol/L（OR = 5.286、95%CI：3.563～6.502、P < 0.001）和白细胞（WBC）计数≥ 10 × 109/L（OR = 4.879、95%CI：2.165～6.361、P = 0.003）均为预后不良的独立危险因素，逐步回归分析显示这6个临床指标与HFMD患儿预后不良关联最紧密；经验证显示预测模型具有良好的准确性和区分度。风险评分显示高危组HFMD患儿预后不良概率显著高于低/中危组（χ2 = 6.032、P = 0.010）；该风险评分系统训练集数据绘制的受试者工作特征曲线（ROC）敏感度和特异度分别为78.11%和77.95%，曲线下面积（AUC）为0.859（95%CI：0.815～0.887），验证集ROC曲线敏感度和特异度分别为77.94%和77.72%，AUC为0.854（95%CI：0.811～0.885）。

结论

不同年龄、性别、居住特点和季节的儿童HFMD分布存在明显差异，对低龄和散居儿童应加强管理，监测HFMD患儿预后不良风险因素并识别高危患儿有利于早期治疗决策和疗效的提升。

关键词: 手足口病, 风险模型, 流行特征, 预后
Objective

To investigate the epidemic characteristics of hand, foot and mouth disease (HFMD) and analyze the risk factors affecting prognosis, as well as the construction and verification of risk model.

Methods

The clinical data of 232 children with HFMD admitted to Panzhihua Central Hospital of Sichuan Province from January 2017 to October 2023 were collected, retrospectively. According to the prognosis, the patients were divided into two groups: good prognosis group (106 males and 72 females) and poor prognosis group (30 males and 24 females). The clinical data and epidemic characteristics of HFMD were collected, and the independent factors affecting prognosis were analyzed by multivariate Logistic regression and a risk prediction model was established.

Results

The incidence of HFMD of children under one-year old was significantly higher than that of over one-year old (P < 0.001), the incidence of HFMD of female children was significantly lower than that of male children (χ2 = 2.372, P = 0.039), the incidence in summer was significantly higher than that in the other three seasons (χ2 = 9.231, P < 0.001), the incidence of scattered children was higher than that of nursery children and other living types (P < 0.001). Multivariate Logistic regression analysis showed that age ≤ 2 years old (OR = 3.668, 95%CI: 1.110-5.332, P = 0.011), interleukin-6 (IL-6) > 25 ng/L (OR = 4.968, 95%CI: 2.382-6.470, P = 0.001), tumor necrosis factor (TNF-α) > 175 ng/L (OR = 5.042, 95%CI: 3.265-7.044, P < 0.001), serum amyloid A (SAA) > 10 mg/L (OR = 3.970, 95%CI: 2.053-6.339, P = 0.013), fasting blood glucose (FBG) ≥ 6.10 mmol/L (OR = 5.286, 95%CI: 3.563-6.502, P < 0.001) and white blood cell (WBC) ≥ 10 × 109 (OR = 4.879, 95%CI: 2.165-6.361, P = 0.003) were all independent risk factors for poor prognosis. Stepwise regression analysis showed that these six clinical indexes were most closely related to poor prognosis of patients with HFMD. The validation showed that the prediction model had good accuracy and discrimination. The risk score showed that the probability of poor prognosis of HFMD patients in the high risk group was significantly higher than those in the low/medium risk group (χ2 = 6.032, P = 0.010). The area under the ROC curve (AUC) drawn by the training set data of the risk scoring system was 0.859 (95%CI: 0.815-0.887), the sensitivity was 78.11%, the specificity was 77.95%; the AUC of the verification set was 0.854 (95%CI: 0.811-0.885), the sensitivity was 77.94%, and the specificity was 77.72%.

Conclusions

There are significant differences in the distribution of children with HFMD among different ages, genders, living characteristics and seasons. Management and supervision should be strengthened for young and scattered children. Monitoring the poor prognostic risk factors of children with HFMD and identifying high-risk children are conducive to early clinical treatment decision-making and the effect of treatment improvement.

Key words: Hand, Foot and mouth disease, Risk model, Epidemic characteristics, Prognosis
表1 232例HFMD患儿的人口学特征
人口学特征 例数 构成比（%） χ2值 P值
年龄     － < 0.001b
< 1岁 103 44.40    
1～2岁 59 25.43c    
3～4岁 27 11.64cd    
5～6岁 23 9.91cd    
7～10岁 20 8.62cd    
性别     2.372 0.039a
男 136 58.62    
女 96 41.38    
居住特点     － < 0.001b
托幼 42 18.10    
散居 173 74.57    
其他 17 7.33    
图1 HFMD患儿发病的季节特征
图2 HFMD患儿发病率箱线图注：A：2017至2023年月均发病率箱线图；B：2017至2023年季度发病率箱线图
表2 预后良好组和预后不良组HFMD患儿一般资料
指标 预后良好组（178例） 预后不良组（54例） 统计量 P值
年龄[例（%）]     χ2 = 4.537 0.033a
> 2岁 60（33.71） 10（18.52）    
≤ 2岁 118（66.29） 44（81.48）    
性别[例（%）]     χ2 = 0.273 0.602a
男 106（59.55） 30（55.56）    
女 72（40.45） 24（44.44）    
病原[例（%）]     χ2 = 0.376 0.945a
CA16 40（22.47） 12（22.22）    
EV71 56（31.46） 18（33.33）    
其他肠道病毒 46（25.84） 15（27.78）    
阴性及不详 36（20.22） 9（16.67）    
发热[例（%）]     χ2 = 7.061 0.008a
有 40（22.47） 22（40.74）    
无 138（77.53） 32（59.26）    
惊厥[例（%）]     χ2 = 0.254 0.614a
有 34（19.10） 12（22.22）    
无 144（80.90） 42（77.78）    
心率[例（%）]     χ2 = 0.000 0.984a
< 160次/min 125（70.22） 38（70.37）    
≥ 160次/min 53（29.78） 16（29.63）    
住院时间[例（%）]     χ2 = 0.032 0.858a
< 14 d 113（63.48） 35（64.81）    
≥ 14 d 65（36.52） 19（35.19）    
就诊时间[例（%）]     χ2 = 2.979 0.084a
< 3 d 83（46.63） 18（33.33）    
≥ 3 d 95（53.37） 36（66.67）    
不典型皮疹[例（%）]     χ2 = 5.872 0.015a
有 69（38.76） 31（57.41）    
无 109（61.24） 23（42.59）    
CRP（ ± s，mg/L） 13.32 ± 4.06 13.96 ± 3.42 t = 1.050 0.295
PCT（ ± s，ng/mL） 57.21 ± 7.02 57.03 ± 7.11 t = 0.165 0.869
SAA（ ± s，mg/L） 2.12 ± 0.41 69.85 ± 7.26 t = 124.432 < 0.001
LTB4（ ± s，ng/L） 26.03 ± 6.28 44.15 ± 13.26 t = 13.855 < 0.001
COX-2（ ± s，µg/L） 23.78 ± 5.82 45.01 ± 12.84 t = 17.074 < 0.001
IL-6（ ± s，ng/L） 18.93 ± 3.46 48.17 ± 13.46 t = 26.365 < 0.001
TNF-α（ ± s，ng/L） 58.57 ± 6.83 269.54 ± 41.26 t = 65.624 < 0.001
hs-cTnT（ ± s，µg/L） 0.08 ± 0.03 3.19 ± 1.08 t = 38.563 < 0.001
NSE（ ± s，µg/L） 6.64 ± 1.68 20.25 ± 3.76 t = 37.595 < 0.001
FBG [例（%）]     χ2 = 8.886 0.003a
< 6.10 mmol/L 125（70.22） 26（48.15）    
≥ 6.10 mmol/L 53（29.78） 28（51.85）    
WBC计数[例（%）]     χ2 = 5.563 0.018a
< 10 × 109/L 132（74.16） 31（57.41）    
≥ 10 × 109/L 46（25.84） 23（42.59）    
表3 HFMD患儿预后不良的多因素Logistic回归分析
指标 β值 S.E.值 Wald χ2值 OR值 95%CI P值
年龄 1.300 0.610 4.539 3.668 1.110～5.332 0.011
发热 1.198 0.695 2.969 3.312 0.924～5.679 0.087
不典型皮疹 0.862 0.662 1.697 2.369 0.872～4.665 0.072
SAA 1.379 0.579 5.671 3.970 2.053～6.339 0.013
LTB4 0.960 0.631 2.313 2.611 0.791～3.592 0.064
COX-2 1.189 0.644 3.411 3.285 0.921～5.411 0.070
IL-6 1.603 0.560 8.194 4.968 2.382～6.470 0.001
TNF-α 1.618 0.482 11.266 5.042 3.265～7.044 < 0.001
hs-cTnT 1.116 0.693 2.594 3.053 0.888～5.421 0.075
NSE 1.201 0.734 2.678 3.324 0.987～5.708 0.111
FBG 1.665 0.519 10.293 5.286 3.563～6.502 < 0.001
WBC 1.585 0.526 9.079 4.879 2.165～6.361 0.003
图4 基于逐步回归的HFMD患儿预后不良风险因素筛选注：A：AIC分布图；B：训练集和验证集在不同临床因素的构建预后模型一致性指数：1：年龄；2：IL-6；3：SAA；4：TNF-α；5：FBG；6：WBC；7：WBC/FBG/TNF-α；8：WBC/FBG/TNF-α/SAA；9：WBC/FBG/TNF-α/SAA/IL-6；10：WBC/FBG/TNF-α/SAA/IL-6/年龄
表4 HFMD患儿预后不良危险因素在训练集和验证集的C指数
危险因素 训练集 验证集
P值 C指数 95%CI P值 C指数 95%CI
年龄 < 0.001 0.432 0.413～0.662 < 0.001 0.430 0.326～0.522
IL-6 < 0.001 0.511 0.542～0.578 < 0.001 0.509 0.487～0.593
SAA < 0.001 0.529 0.517～0.574 < 0.001 0.526 0.509～0.591
TNF-α < 0.001 0.572 0.539～0.621 < 0.001 0.566 0.524～0.618
FBG < 0.001 0.617 0.589～0.631 < 0.001 0.621 0.584～0.703
WBC < 0.001 0.646 0.628～0.683 < 0.001 0.652 0.620～0.662
图5 预测模型的准确度评价注：A：训练集；B：验证集
图6 各危险分层患儿预后分布
图7 评分系统及预测模型判断患儿预后的ROC曲线注：A：训练集；B：验证集
[1]
Jiang Y, Xu J, Lai H, et al. Association between meteorological parameters and hand, foot and mouth disease in mainland china: A systematic review and meta-analysis[J]. Iran J Public Health,2021,50(9):1757-1765.
[2]
Ang WX, Sarasvathy S, Kuppusamy UR, et al. In vitro antiviral activity of medicinal mushroom Ganoderma neo-japonicum Imazeki against enteroviruses that caused hand, foot and mouth disease[J]. Trop Biomed,2021,38(3):239-247.
[3]
Verma S, Singal A. Nail changes in hand-foot-and-mouth disease (HFMD)[J]. Indian Dermatol Online J,2020,12(4):656-657.
[4]
Cui Y, Yang YN, Zheng RR, et al. Epidemiological characteristics of hand, foot, and mouth disease clusters during 2016-2020 in Beijing, China[J]. J Med Virol,2022,94(10):4934-4943.
[5]
Oska S, Bedford LM, Potts GA. Alopecia totalis following hand-foot-and-mouth disease[J]. Pediatr Dermatol,2021,38(3):640-642.
[6]
Gomes S, Santos S, Ferreira Maia I, et al. Hand-foot-mouth disease in an adult[J]. Cureus,2023,15(1):e33670-e33675.
[7]
Wang X, Liu H, Li Y, et al. Relationship between polymorphism of receptor SCARB2 gene and clinical severity of enterovirus-71 associated hand-foot-mouth disease[J]. Virol J,2021,18(1):132-141.
[8]
中华人民共和国国家卫生和计划生育委员会. 手足口病诊疗指南(2018年版)[J]. 传染病信息,2018,25(6):8-13.
[9]
潘静静, 卫海燕, 王若琳, 等. 手足口病预后因素的因子分析及预后预测模型[J]. 实用预防医学,2020,27(8):1014-1016.
[10]
Dong Y, Wan Z, Li S, et al. Genomic phylogenetic analyses of four major hand, foot and mouth disease-related enteroviruses[J]. Acta Virol,2022,66(1):27-38.
[11]
闫凯悦, 邓慧玲, 张玉凤, 等. 胰岛素样生长因子-1与手足口病重症化的相关性研究[J/CD]. 中华实验和临床感染病杂志(电子版),2023,17(3):151-157.
[12]
Di Lella E, Angelini F, Campagnano S, et al. An unusual location of hand, foot and mouth disease[J]. J Ultrasound,2022,25(2):361-364.
[13]
Peng Y, He W, Zheng Z, et al. Factors related to the mortality risk of severe hand, foot, and mouth diseases (HFMD): a 5-year hospital-based survey in Guangxi, Southern China[J]. BMC Infect Dis,2023,23(1):144-152.
[14]
Li C, Zhang W, Chang X, et al. The upregulation of peripheral blood polyamine metabolites spermidine and spermine in children with hand, foot, mouth disease is related to enterovirus 71 capsid protein VP1, but not VP4[J]. Transl Pediatr,2023,12(2):194-207.
[15]
Jia J, Kong F, Xin X, et al. Epidemiological characteristics of hand, foot, and mouth disease outbreaks in qingdao, 2009-2018[J]. Iran J Public Health,2021,50(5):999-1008.
[16]
Chen B, Yang Y, Xu X, et al. Epidemiological characteristics of hand, foot, and mouth disease in China: A meta-analysis[J]. Medicine (Baltimore),2021,100(20):e25930-e25939.
[17]
He X, Zhang M, Zhao C, et al. From monovalent to multivalent vaccines, the exploration for potential preventive strategies against hand, foot, and mouth disease (HFMD)[J]. Virol Sin,2021,36(2):167-175.
[18]
Santangelo OE, Gianfredi V, Provenzano S, et al. Digital epidemiology and infodemiology of hand-foot-mouth disease (HFMD) in Italy. Disease trend assessment via Google and Wikipedia[J]. Acta Biomed,2023,94(4):e2023107-e2023115.
[19]
Xie Y, Hu Q, Jiang W, et al. Laboratory indicators for identifying hand, foot, and mouth disease severity: A systematic review and Meta-analysis[J]. Vaccines (Basel),2022,10(11):1829-1844.
[20]
Mohanty MC, Varose SY, Saxena VK. Susceptibility and cytokine responses of human neuronal cells to multiple circulating EV-A71 genotypes in India[J]. Sci Rep,2021,11(1):17751-17764.
[21]
Swain SK, Panda S, Sahu BP, et al. Activation of host cellular signaling and mechanism of enterovirus 71 viral proteins associated with hand, foot and mouth disease[J]. Viruses,2022,14(10):2190-2207.
[22]
Techasaensiri C, Wongsa A, Puthanakit T, et al. Response of severe EV71-infected patients to hyperimmune plasma treatment: A pilot study[J]. Pathogens,2021,10(5):625-633.
[23]
Yi Z, Pei S, Suo W, et al. Epidemiological characteristics, routine laboratory diagnosis, clinical signs and risk factors for hand, -foot -and -mouth disease: A systematic review and meta-analysis[J]. PLoS One,2022, 17(4):e0267716-e0267730.
[24]
刘怀彬, 张振坤, 闵婕. 肺炎支原体肺炎患儿支气管肺泡灌洗液白细胞介素-4,白细胞介素-6,干扰素-γ水平与病情和肺功能的关系[J/CD]. 中华实验和临床感染病杂志(电子版),2022,16(1):25-32.
[25]
Shao P, Wu X, Li H, et al. Clinical significance of inflammatory cytokine and chemokine expression in hand, foot and mouth disease[J]. Mol Med Rep,2017,15(5):2859-2866.
[26]
Lee JY, Hall JA, Kroehling L, et al. Serum amyloid a proteins induce pathogenic th17 cells and promote inflammatory disease[J]. Cell,2020,180(1):79-91.e16.
[27]
Vietri L, Fui A, Bergantini L, et al. Serum amyloid A: A potential biomarker of lung disorders[J]. Respir Investig,2020,58(1):21-27.
[28]
冯一平, 孙大鹏, 王显军, 等. DLNM和LSTM神经网络对临沂市手足口病发病的预测效果比较[J]. 山东大学学报(医学版),2022,60(2):96-101.
[29]
Yoshida K, Fujimoto T, Muramatsu M, et al. Prediction of hand, foot, and mouth disease epidemics in Japan using a long short-term memory approach[J]. PLoS One,2022,17(7):e0271820.
[30]
Ji TJ, Cheng Q, Zhang Y, et al. A novel early warning model for hand, foot and mouth disease prediction based on a graph convolutional network[J]. Biomed Environ Sci,2022,35(6):494-503.
[1] 孙姚承, 汤建军, 张伟元, 刘传磊. 阳性淋巴结比和阳性淋巴结对数比对结直肠癌患者预后价值的研究[J]. 中华普通外科学文献(电子版), 2024, 18(03): 204-208.
[2] 蔡大明, 陆晓峰, 王行舟, 王萌, 刘颂, 夏雪峰, 沈晓菲, 杜峻峰, 管文贤. 三级淋巴结构在胃神经内分泌瘤中的预后价值及预后预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 401-405.
[3] 达热拜·热达提, 刘林, 赵为民, 孟涛, 雷程, 金博, 毕建军, 李新宇, 王海江. 中低位直肠癌新辅助放化疗后侧方淋巴结清扫术的临床观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 415-418.
[4] 李娇娇, 张军, 徐顺. 全程新辅助治疗联合全直肠系膜切除术对局部进展期直肠癌预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 283-286.
[5] 王东阳, 林琳, 娄熙彬. SII对局部进展期胃癌nCRT＋腹腔镜胃癌根治术后并发症及预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 315-318.
[6] 聂彬, 赵铁军, 于云宝, 李欢, 谢林峻. 单孔加一孔腹腔镜手术与传统腹腔镜手术治疗乙状结肠癌的疗效与分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 330-333.
[7] 颜晓敏, 崔嵘嵘. 23例乳腺佩吉特病的经验交流[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 353-354.
[8] 周慧宇, 吕定阳, 双卫兵. 联合系统性免疫炎症指数和预后营养指数预测腹腔镜肾切除术后肾癌患者的预后[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 225-231.
[9] 朱显钟, 李金雨, 于忠英, 温路生. 淋巴结平均直径与无淋巴结转移肾癌病理特征及预后关系研究[J]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(02): 146-151.
[10] 曾谣, 谢琴, 陈显育, 王平根, 毛玲秋, 何丹玲, 杜飞, 郑希彦, 何函樨. CDC42EP2基因与肝癌预后、免疫细胞浸润关系及其对细胞迁移侵袭的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 363-369.
[11] 陈显育, 曾谣, 莫钊鸿, 翟航, 张广权, 钟造茂, 陈署贤. 生物信息学分析CETP基因在肝癌中表达及其对预后和免疫的影响[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 214-219.
[12] 胡欣芫, 杨智義, 赵成俊, 张秋雨, 张挽乾, 潘佰猛, 张灵强. 急性胰腺炎评分系统预测病情严重程度的研究进展[J]. 中华肝脏外科手术学电子杂志, 2024, 13(02): 239-243.
[13] 周建芳, 罗旭颖, 张琳琳, 李宏亮, 杨燕琳, 陈光强, 石广志. 开颅术后危重患者急性肾损伤的发病率、危险因素及其对预后的影响[J]. 中华重症医学电子杂志, 2024, 10(02): 148-156.
[14] 宋韵韵, 孙元慧, 黄登超, 郭秦乐, 高兰, 李昊, 石秦东. 危重症患者CRRT过程中低磷血症发生与预后的回顾性研究[J]. 中华重症医学电子杂志, 2024, 10(02): 164-172.
[15] 安亚楠, 王端然, 郭甜甜, 武希润. 幽门螺杆菌阴性胃黏膜相关淋巴组织淋巴瘤的研究进展[J]. 中华消化病与影像杂志(电子版), 2024, 14(03): 268-274.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号